AbbVie
ABBV
2,599 hedge funds and large institutions have $128B invested in AbbVie in 2020 Q4 according to their latest regulatory filings, with 357 funds opening new positions, 1,108 increasing their positions, 874 reducing their positions, and 89 closing their positions.
301% more first-time investments, than exits
New positions opened: 357 | Existing positions closed: 89
33% more funds holding in top 10
Funds holding in top 10: 121 → 161 (+40)
27% more repeat investments, than reductions
Existing positions increased: 1,108 | Existing positions reduced: 874
21% more capital invested
Capital invested by funds: $106B → $128B (+$22.3B)
10% more funds holding
Funds holding: 2,366 → 2,599 (+233)
0.76% less ownership
Funds ownership: 68.7% → 67.94% (-0.76%)
16% less call options, than puts
Call options by funds: $2.23B | Put options by funds: $2.64B
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Berkshire Hathaway
Omaha,
Nebraska
|
+$410M |
| 2 |
GQG Partners
Ft. Lauderdale,
Florida
|
+$309M |
| 3 |
Boston Partners
Boston,
Massachusetts
|
+$264M |
| 4 |
Morgan Stanley
New York
|
+$250M |
| 5 |
BlackRock
New York
|
+$231M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$712M |
| 2 |
VOYA Investment Management
Atlanta,
Georgia
|
-$340M |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$337M |
| 4 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$298M |
| 5 |
Capital Research Global Investors
Los Angeles,
California
|
-$277M |
ABBV Hedge Fund Activity: Q4 2020 in Review
2,599 of the 5,676 institutional investors tracked by Wall St. Rank reported a position in AbbVie (ABBV) for Q4 2020, worth a combined $128B — up 21% from $106B a quarter earlier.
Buyers outnumbered sellers: 357 funds opened new ABBV positions and 89 closed out — a net gain of 268 holders — while 1,108 added to existing stakes and 874 trimmed.
The largest buyer was Berkshire Hathaway, adding an estimated $410M. The largest seller was Renaissance Technologies, cutting an estimated $712M.
- 2,599 institutional investors held AbbVie (ABBV) as of Q4 2020, up from 2,366 in Q3 2020.
- Funds reported $128B of AbbVie stock for Q4 2020, up 21% quarter-over-quarter.
- 357 funds opened new AbbVie positions in Q4 2020 and 89 closed out, a net change of +268 holders.
- The largest AbbVie buyer in Q4 2020 was Berkshire Hathaway, an estimated $410M added.
- The largest AbbVie seller in Q4 2020 was Renaissance Technologies, an estimated $712M sold.
Based on aggregated 13F filings for Q4 2020.